Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Origin Life Sciences Inc. is currently dealing with 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This single matter is located within 1 distinct art unit, showing a focused technical scope for the company's active applications. This concentration in 1 art unit allows the applicant to tailor its responses to the specific technical expertise and standards of that administrative group.
The busiest examiner for the portfolio is ARNOLD, ERNST V, who is responsible for the 1 pending office action. Because there is only 1 distinct examiner, the company's immediate prosecution path is determined by a single set of examiner interactions. This relationship with ARNOLD, ERNST V is the primary factor in the current advancement of the company's biotechnology claims.
With 1 pending office action active, the company's immediate patenting goals are focused on this 1 proceeding. The 1 distinct art unit provides a singular administrative environment for the review of the company's pharmaceutical innovations. Practitioners should prioritize addressing the specific concerns raised by the 1 assigned examiner to facilitate a timely conclusion to the prosecution phase.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ARNOLD, ERNST V | 1 | 48.2% | +12.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18570363 | METHODS OF USING A PLASMA-GENERATED STREAM OF NO-CONTAINING GAS FOR TREATMENT OF A SPECTRUM OF MEDICAL CONDITIONS | ARNOLD, ERNST V | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18570363 | METHODS OF USING A PLASMA-GENERATED STREAM OF NO-CONTAINING GAS FOR TREATMENT OF A SPECTRUM OF MEDICAL CONDITIONS | ARNOLD, ERNST V | — |
| Art Unit | Apps |
|---|---|
| 1613 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18570363 | METHODS OF USING A PLASMA-GENERATED STREAM OF NO-CONTAINING GAS FOR TREATMENT OF A SPECTRUM OF MEDICAL CONDITIONS | ARNOLD, ERNST V | 1613 | §102§103§112 | Non-Final OA | — | Pending | Dec 14, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialOrigin Life Sciences Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Ernst V Arnold has the most, with 1 of Origin Life Sciences Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
